<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514852</url>
  </required_header>
  <id_info>
    <org_study_id>AG9818-002</org_study_id>
    <nct_id>NCT00514852</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will
      be compared to a currently-available artificial tear
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score</measure>
    <time_frame>Change from baseline at Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 30 in Schirmer Test, With Anesthesia</measure>
    <time_frame>Change from baseline at Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein</measure>
    <time_frame>Change from baseline at Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptability Score (Dryness) at Day 30</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptability Score (Vision) at Day 30</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein</measure>
    <time_frame>Change from baseline at Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein</measure>
    <time_frame>Change from baseline at Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score</measure>
    <time_frame>Change from baseline at Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">316</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboxymethylcellulose and Glycerin based artificial tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboxymethylcellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboxymethylcellulose and Glycerin based artificial tear</intervention_name>
    <description>1 to 2 drops into each eye as needed but at least twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboxymethylcellulose</intervention_name>
    <description>1 to 2 drops into each eye as needed but at least twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Refresh Plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild, moderate or Severe Symptoms of Dry Eye

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Use of systemic medications affecting dry eye

          -  Pregnancy or planning a pregnancy

          -  Contact lens wear
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <results_first_submitted>May 19, 2009</results_first_submitted>
  <results_first_submitted_qc>November 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2009</results_first_posted>
  <last_update_submitted>November 10, 2009</last_update_submitted>
  <last_update_submitted_qc>November 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Allergan, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
          <description>1 to 2 drops into each eye as needed but at least twice daily</description>
        </group>
        <group group_id="P2">
          <title>Carboxymethylcellulose Based Artificial Tear</title>
          <description>1 to 2 drops into each eye as needed but at least twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
          <description>1 to 2 drops into each eye as needed but at least twice daily</description>
        </group>
        <group group_id="B2">
          <title>Carboxymethylcellulose Based Artificial Tear</title>
          <description>1 to 2 drops into each eye as needed but at least twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="159"/>
            <count group_id="B3" value="316"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score</title>
        <description>Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)</description>
        <time_frame>Change from baseline at Day 30</time_frame>
        <population>Intent to Treat Population (Modified)</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score</title>
          <description>Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)</description>
          <population>Intent to Treat Population (Modified)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="18.1"/>
                    <measurement group_id="O2" value="45.2" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="14.9"/>
                    <measurement group_id="O2" value="-13.6" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="16.4"/>
                    <measurement group_id="O2" value="-16.6" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 30 in Schirmer Test, With Anesthesia</title>
        <description>Schirmer Test measures the rate of the secretion of tears</description>
        <time_frame>Change from baseline at Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 30 in Schirmer Test, With Anesthesia</title>
          <description>Schirmer Test measures the rate of the secretion of tears</description>
          <population>Intent to Treat Population</population>
          <units>mm/5min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="7.2"/>
                    <measurement group_id="O2" value="8.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="5.1"/>
                    <measurement group_id="O2" value="1.2" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="6.9"/>
                    <measurement group_id="O2" value="1.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein</title>
        <description>Measures the stability of tear film. The average of 3 measures.</description>
        <time_frame>Change from baseline at Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein</title>
          <description>Measures the stability of tear film. The average of 3 measures.</description>
          <population>Intent to Treat Population</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.1"/>
                    <measurement group_id="O2" value="4.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.3"/>
                    <measurement group_id="O2" value="0.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.7"/>
                    <measurement group_id="O2" value="0.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Acceptability Score (Dryness) at Day 30</title>
        <description>Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all).</description>
        <time_frame>Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Acceptability Score (Dryness) at Day 30</title>
          <description>Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all).</description>
          <population>Intent to Treat Population</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="22.8"/>
                    <measurement group_id="O2" value="44.6" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" spread="21.1"/>
                    <measurement group_id="O2" value="57.7" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="22.7"/>
                    <measurement group_id="O2" value="63.8" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Acceptability Score (Vision) at Day 30</title>
        <description>Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better).</description>
        <time_frame>Day 30</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Acceptability Score (Vision) at Day 30</title>
          <description>Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better).</description>
          <population>Intent to treat population</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="22.4"/>
                    <measurement group_id="O2" value="54.2" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="17.8"/>
                    <measurement group_id="O2" value="62.6" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="20.1"/>
                    <measurement group_id="O2" value="66.4" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Vision Subscale of the Ocular Surface Disease Index Questionnaire© at Day 30</title>
        <description>Vision subscale of the Ocular Surface Disease Index Questionnaire© is measured on 6 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)</description>
        <time_frame>Day 30</time_frame>
        <population>Intent to Treat Population (Modified)</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vision Subscale of the Ocular Surface Disease Index Questionnaire© at Day 30</title>
          <description>Vision subscale of the Ocular Surface Disease Index Questionnaire© is measured on 6 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)</description>
          <population>Intent to Treat Population (Modified)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="21.5"/>
                    <measurement group_id="O2" value="41.6" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="20.0"/>
                    <measurement group_id="O2" value="26.9" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="20.4"/>
                    <measurement group_id="O2" value="25.6" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Ocular Surface Staining With Fluorescein (Central Cornea) at Day 30</title>
        <description>Central staining score is based on modified Oxford Scheme measured on a scale of 0-5 (0= no staining, 5= most severe staining)</description>
        <time_frame>Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Staining With Fluorescein (Central Cornea) at Day 30</title>
          <description>Central staining score is based on modified Oxford Scheme measured on a scale of 0-5 (0= no staining, 5= most severe staining)</description>
          <population>Intent to Treat Population</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.8"/>
                    <measurement group_id="O2" value="0.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.6"/>
                    <measurement group_id="O2" value="0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein</title>
        <description>Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining)</description>
        <time_frame>Change from baseline at Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein</title>
          <description>Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining)</description>
          <population>Intent to Treat Population</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.3"/>
                    <measurement group_id="O2" value="4.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.3"/>
                    <measurement group_id="O2" value="-0.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.4"/>
                    <measurement group_id="O2" value="-1.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein</title>
        <description>Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining)</description>
        <time_frame>Change from baseline at Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein</title>
          <description>Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining)</description>
          <population>Intent to Treat Population</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="4.4"/>
                    <measurement group_id="O2" value="5.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.1"/>
                    <measurement group_id="O2" value="-1.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.3"/>
                    <measurement group_id="O2" value="-1.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score</title>
        <description>Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe)</description>
        <time_frame>Change from baseline at Day 30</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Based Artificial Tear</title>
            <description>1 to 2 drops into each eye as needed but at least twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score</title>
          <description>Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe)</description>
          <population>Intent to Treat Population</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.7"/>
                    <measurement group_id="O2" value="2.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.8"/>
                    <measurement group_id="O2" value="-0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.0"/>
                    <measurement group_id="O2" value="-0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carboxymethylcellulose and Glycerin Based Artificial Tear</title>
          <description>1 to 2 drops into each eye as needed but at least twice daily</description>
        </group>
        <group group_id="E2">
          <title>Carboxymethylcellulose Based Artificial Tear</title>
          <description>1 to 2 drops into each eye as needed but at least twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>(714)246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

